Bortezomib blocked vascular endothelial growth factor (VEGF) and IL-6 secretion by endothelial cells from myeloma patients and reduced VEGF, IL-6, insulin-like growth factor-I, Angiopoietin (Ang1/Ang2) transcription. The gene discussed is VEGFA; the disease is plasma cell myeloma.